Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SenesTech, Inc. (NASDAQ: SNES) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. SenesTech is a biotechnology company focused on fertility control for managing rodent populations, and its filings offer detailed information on its operations, financing activities, and governance.
Key documents available through EDGAR and summarized with AI-powered insights include Form 10-K annual reports, which describe the business, risk factors, and strategy around products such as ContraPest® and the Evolve rodent birth control line, and Form 10-Q quarterly reports, which update investors on revenues, gross margins, operating expenses, and cash position. These periodic reports help readers understand how SenesTech’s fertility control products and multi-channel distribution efforts are reflected in its financial statements.
SenesTech also files numerous Form 8-K current reports documenting material events. Recent 8-K filings describe warrant inducement agreements and related financings, at-the-market offering prospectus supplements, the appointment and compensation of an interim chief operating officer, board changes, and the release of quarterly financial results. These filings provide structured detail on capital raises, equity-linked securities, and key management decisions.
Through this page, users can also review registration statements and prospectus supplements referenced in 8-Ks, which outline at-the-market equity programs and additional registered shares. Stock Titan’s tools surface new filings in real time and apply AI-generated summaries to highlight the main points of lengthy documents, helping investors quickly locate information on SenesTech’s financial condition, equity offerings, and significant corporate events without reading every page manually.
SenesTech, Inc. reported that Glenbrook Capital Management, acting as investment manager for PFS Trust and the Glenbrook Capital Management Inc. Employee Profit-Sharing Plan, indirectly bought a total of 85,901 shares of Common Stock on February 17–19, 2026.
The shares were purchased in open-market transactions at prices between $2.29 and $2.402 per share, increasing these entities’ reported indirect holdings to 704,211 shares of SenesTech Common Stock.
Glenbrook Capital Management, a 10% owner of SenesTech, Inc. (SNES), reported three indirect open-market purchases of common stock. On February 11, 12, and 13, 2026, investment entities it manages bought 8,000, 7,956, and 15,390 SenesTech common shares at per-share prices between $1.7205 and $1.8912. After these transactions, a total of 633,700 common shares were reported as beneficially owned on an indirect basis. The shares are held by PFS Trust and the Glenbrook Capital Management Inc. Employee Profit-Sharing Plan, with Glenbrook acting as investment manager and disclaiming beneficial ownership except to the extent of any pecuniary interest.
Glenbrook Capital Management, identified as a 10% owner of SenesTech, Inc., reported indirect purchases of the company’s common stock through entities it manages. On February 4, 2026, PFS Trust and Glenbrook Capital Management Inc. Employee Profit-Sharing Plan together bought 5,685 shares at
Glenbrook Capital Management, as reporting person, disclosed two indirect open‑market purchases of SenesTech, Inc. common stock made for PFS Trust and an employee profit‑sharing plan. On January 30, 2026, 5,399 shares were bought at $1.8718 per share. On February 2, 2026, 42,739 shares were bought at $1.9752 per share.
After these trades, 551,046 and then 593,785 SenesTech shares were reported as indirectly beneficially owned. The filing notes that Glenbrook Capital Management serves as investment manager to the entities holding the shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
Glenbrook Capital Management filed an amended Schedule 13G reporting beneficial ownership of 593,785 shares of SenesTech, Inc. common stock, equal to 11.4% of the class. This percentage is based on 5,223,015 shares outstanding as of November 7, 2025.
The shares are held through PFS Trust and Glenbrook Capital Management Inc. Employee Profit-Sharing Plan, for which Glenbrook serves as investment manager. The certification states the holdings were not acquired and are not held for the purpose or effect of changing or influencing control of SenesTech.
Glenbrook Capital Management, as a 10% owner of SenesTech, Inc. (SNES), reports indirect holdings of 545,647 shares of Common Stock and 90,000 Series I Common Stock Warrants. The securities are held by PFS Trust and Glenbrook Capital Management Inc. Employee Profit-Sharing Plan.
Glenbrook Capital Management serves as investment manager to these entities and disclaims beneficial ownership except for any pecuniary interest. The Series I Warrants, with a $5.25 exercise price and expiring on 11/13/2026, are subject to 4.99% and 9.99% ownership blockers that currently prevent their exercise.
SenesTech, Inc. filed an amended report to add a missing conformed signature, and confirmed that President and Chief Executive Officer Joel L. Fruendt has notified the company he will retire from both his executive role and the Board.
His retirement will be effective on the earlier of June 30, 2026, or the appointment of a successor CEO. Under a separation agreement, he will receive continued base salary through December 15, 2026, company-paid or reimbursed health insurance premiums through December 31, 2026, and accelerated vesting of his stock options, subject to his release of claims. The Board appointed Jamie Bechtel as Interim Executive Chair, with annual compensation of $247,500 for that role in addition to existing Board-related pay.
SenesTech, Inc. announced that President and Chief Executive Officer Joel L. Fruendt plans to retire from the company and its Board, effective on the earlier of June 30, 2026 or the appointment of a successor CEO. The company and Mr. Fruendt entered into a separation agreement that provides continued base salary through December 15, 2026, health insurance premiums paid or reimbursed through December 31, 2026, and accelerated vesting of his stock options, subject to his signing a release of claims.
The Board appointed Jamie Bechtel as Interim Executive Chair on January 26, 2026. She will receive $247,500 per year for this role, in addition to any existing compensation for her service on the Board and its committees.
SenesTech, Inc. (SNES)
SenesTech, Inc. (SNES)1 share of common stock on 11/14/2025 at a price of $2.75 per share. Following this transaction, the reporting person held 0 shares of SenesTech common stock in direct ownership. The filing is signed by /s/ Thomas C. Chesterman, Attorney-in-Fact on 11/17/2025.